Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases.

Eli Lilly & Co. is tapping the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of ...

Global Diabetes Drug Market growth is driven by the rising incidence of diabetes and increasing adoption of innovative treatment solutions.Austin, United States, Feb. 10, 2025 (GLOBE NEWSWIRE) -- ...

OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and ...

Market report delivers crucial insights into the market's growth trajectory and the primary revenue drivers anticipated ...

Former Wimbledon tennis star Boris Becker and his ex-wife Lilly were married for nine years and welcomed son Amadeus, 14, ...

Olix Pharmaceuticals signed a $630 million licensing deal with Eli Lilly to develop treatments for cardiovascular and ...

Everything we covered on WTR over the past seven days, and all you need to know from the world of trademarks to set yourself ...

Bain Capital said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.